Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer

Anna L McGuire*,1, Curtis B Hughesman2, Melissa K McConchy3, Barb Melosky4,5, Stephen Lam4,6, Renelle Myers4,6, John Yee1, Ernest Tang1 & Stephen Yip2,7

1Department of Surgery, Division of Thoracic Surgery, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
2Department of Pathology and Laboratory Medicine, BC Cancer, Cancer Genetics & Genomics Laboratory, Vancouver, BC, Canada
3Contextual Genomics Inc., Vancouver, BC, Canada
4Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Vancouver, BC, Canada
5Medical Oncology, University of British Columbia, Vancouver, BC, Canada
6Department of Medicine, Divisions of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada
7Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

*Author for correspondence: anna.mcguire@vch.ca

Stage I/II NSCLC surgical patients with MRD undergoing liquid biopsy postoperatively would be the ideal target population for assessment of the impact of adjuvant targeted systemic therapy on disease-free survival.

First draft submitted: 20 December 2019; Accepted for publication: 27 January 2020; Published online: 21 February 2020

Keywords: biomarkers • genetics • lung • lung cancer • molecular oncology • oncology • personalized medicine • surgery • surgical

Lung cancer remains the number one cause of cancer death globally [1,2]. Unfortunately, in an unscreened population, the majority of patients diagnosed with lung cancer (80%) present in stage III/IV [3,4]. Patients with the best prospect for cure include those with early stage (I/II) NSCLC undergoing curative intent surgical therapy. These early-stage patients have no clinical or radiological signs of overt cancer. Despite receiving curative intent treatment, many still experience recurrent disease and poor long-term survival [5]. This may be due to occult molecular residual disease (MRD) that is undetectable with current standard technology, yet is an important source for future cancer recurrence [6].

Existing postoperative detection methods are limited to microscopic residual disease assessment of the surgical specimen margins (traditional histopathology), and gross disease detection with imaging (positron emission tomography and CT scans) [7]. Liquid biopsy for ctDNA in patient blood has been identified as an attractive, noninvasive modality for detection of MRD after curative intent local therapy [8–12].

Stage I/II NSCLC surgical patients with MRD undergoing liquid biopsy postoperatively would be the ideal target population for assessment of the impact of adjuvant targeted systemic therapy on disease-free survival. In the context of a clinical trial, blood-based stratification of the study population by presence of genetic alterations for targeted systemic therapy selection is the ideal avenue for introduction of this technology into postoperative clinical practice [13].

Despite the attractive potential, several limitations must be overcome in order to offer this testing reliably for the postoperative MRD clinical setting. Here, we discuss key theoretical and technical principles relating to the limit of detection, and strategies to increase the probability of ctDNA detection in cell free DNA for analysis using highly sensitive next generation sequencing (NGS). The following discussion assumes optimized laboratory plasma isolation and DNA extraction techniques, as these will inherently impact assay sensitivity with respect to both cell free DNA yield and quality [14].
Most healthy individuals rarely have more than 10 ng of cell free DNA per ml plasma, most of which originates from hemopoietic cells [14–16]. Although much remains to be learned about diurnal variation and clearance mechanisms of cell free DNA [17–20], various physiologic stress events have been shown to influence its release at the cellular level from noncancerous host cells. Such cell death inducing events include: intense exercise [21,22], autoimmune disease [23], stroke [24,25], myocardial infarction [26], trauma [27] and sepsis [28]. The fraction of cell free DNA in patient blood that arises from the tumor itself is referred to as ctDNA. Fragmented tumor-specific DNA can be shed into blood passively via apoptosis, necrosis, phagocytosis or actively with the secretion of microvesicle exosomes [13,29–32]. The ctDNA levels in blood are generally low, and have been shown to be directly proportional to tumor burden and clinical stage in NSCLC and other solid tumors [33–35]. Cell free DNA has a short half-life in the circulation, with a range of 16–150 min reported [17,20]. As such, blood-based detection of the ctDNA molecular portion has potential to be a real time measure of tumor burden.

Several targeted plasma liquid biopsy ctDNA platforms have been previously reported for use in NSCLC [12,36–41]. Such highly sensitive targeted NGS panel assays routinely report the ability to detect a level of variant allele frequency (VAF) in plasma, which often assume that enough cell free DNA is available to identify these extremely low frequency variants.

In the setting of early stage NSCLC cancer however, it is valuable to conceptualize how VAF depends on both total cell free DNA input for testing, and number of ctDNA molecules present in patient blood for sampling [14]. For instance, the quantity of ctDNA in the cell free DNA fraction in patients with stage I tumors has been measured to be approximately tenfold lower than that in patients with stage IV disease [12,13]. In the postoperative MRD setting, based on the inherent decreased quantities of tumor DNA shedding from early stage NSCLC, the importance of detecting alterations present at a VAF of <0.1% has been established [8,9,12,33]. The probability of detecting a certain number of ctDNA molecules at a low volume in blood follows the Poisson distribution, where not all blood samples will be ‘positive’ even with a method that can detect individual ctDNA molecules [42]. Johansson et al. have demonstrated that if it is assumed that one ctDNA molecule is required for genetic alteration detection, in order to fully maximize the utility of NGS approaches >3.6 ng total input cell free DNA is necessary [14]. Practically this implies that workflow improvements for cell free DNA yield may improve technical sensitivity.

So, how can we as clinician scientists practically increase the probability of ctDNA molecular capture postoperatively? Analyzing larger patient blood volumes to increase the probability of ctDNA molecule detection is one potential avenue to increase limited input DNA [13]. An additional method is to use existing knowledge of the genetic alterations present in the lung tumor tissue to improve analytical sensitivity. Use of matching cancer panels for targeted genetic alteration detection in both lung tumor tissue and plasma may increase the lower limit of ctDNA detection [33,36,39]. Digital PCR on postoperative plasma may then be conducted as needed for known alterations identified in tumor tissue that may be present at low frequency in plasma for quality assurance in optimization of ultrasensitive multiplex cancer panels [13].

Matching reference genetic alterations in resected lung tumor tissue with blood plasma sequencing panels also mitigates the problem of false-positive results from clonal hematopoiesis of indeterminate potential (CHIP). This phenomenon increases with age and may give rise to genetic variants in the blood unrelated to the lung tumor of interest that confound ctDNA detection [43]. CHIP is especially problematic in the setting of MRD detection where the VAF is low [44]. However, CHIP can also be accounted by sequencing matched plasma buffy coat samples to similar depth as ctDNA [43–45]. The probability of ctDNA detection has also been shown to increase with use of multiplex assays, analyzing simultaneously for many independent genetic alterations [14].

Additional advanced NGS methods to increase sensitivity with limited input DNA include both use of unique molecular identifiers either exogenously attached or endogenously inferred from sequence context, and sophisticated error correction bioinformatics analytical approaches [14,37,46]. These advanced methods together help address the technical limitations for detection of low frequency genetic alterations by NGS due to artefactual errors that accumulate during library preparation, target enrichment and sequencing. Artefactual errors are problematic as they lead to false-positive mutations and can mask detection of true biological variants [39,46]. Unique molecular identifiers are short sequences that incorporate a unique barcode onto each molecule in a given tumor DNA sample library. They have been shown to reduce the frequency of false-positive variant calls and increase sensitivity of true low frequency genetic variant detection [37]. The value of incorporating barcodes onto original ctDNA fragments is that the true variant alleles present in the original plasma ctDNA sample can be distinguished from errors introduced during library preparation, target enrichment or sequencing. Any such errors identified can then be removed by bioinformatics analytical approaches.
As outlined in our discussion above, precise methods of ctDNA detection in early stage surgical NSCLC have the potential to transform postoperative clinical practice via noninvasive MRD detection. The identification of tumor-specific genetic alterations using tissue or blood-based NGS tests are helping to drive personalized treatment and remains an important ongoing area of study. There are still no clinically standard NGS assays to identify MRD postoperatively. Ongoing pilot studies in this setting are essential in efforts to decrease the global burden of disease and mortality due to lung cancer.

Financial & competing interests disclosure
AL McGuire receives in-kind research support from Contextual Genomics Inc. MK McConkey is employed by Contextual Genomics Inc. B Melosky has received honoraria from Boehringer Ingelheim, Eli Lilly, Novartis, Pfizer, Roche, Merck, Bristol–Myers Squibb, Novartis and AstraZeneca, and research funding from Roche and Bayer. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References
1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D et al. Global, regional, national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years fro 29 cancer groups, 1990 to 2017. JAMA Oncol. 5(12), 1749–1768 (2019).
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific and cause-specific mortality for 24 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963), 117–171 (2015).
3. McWilliams A, Tammemagi M, Mayo JR et al. Probability of cancer in pulmonary nodules detected on first screening CT. N. Engl. J. Med. 369, 910–919 (2013).
4. The National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 368(21), 1980–1991 (2013).
5. Goldstraw P, Chansky K, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11(1), 39–51 (2015).
6. Pantel K, Alix-Panabières C. Tumour microenvironment: informing on minimal residual disease in solid tumours. Nat. Rev. Clin. Oncol. 14, 325–326 (2017).
7. National Comprehensive Cancer Network. Non-small cell lung cancer NCCN clinical practice guidelines in oncology (2019). www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
8. Chaudhuri AA, Chabon JJ, Lovejoy AF et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 7(12), 1394–1403 (2017).
9. Abbosh C, Birksbak NJ, Wilson GA et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545(7655), 446–451.
10. Chen K, Zhang J, Guan T et al. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 154(3), 1123–1131 (2017).
11. Chen KZ, Lou F, Yang F et al. Circulating tumor DNA detection in early-stage non-small cell. Sci. Rep. 6, 31985 (2016).
12. Newman AM, Brittsman SV, To J et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20(5), 548–554 (2014).
13. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6(5), 479–491 (2016).
14. Johanson G, Andersson D, Filges S, et al. Considerations and quality controls when analyzing cell-free tumor DNA. Biomol. Detect. Quantif. 17, 100078 (2019).
15. Lui YYN, Chik KW, Chiu RWK et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48(3), 421–427 (2002).
16. Snyder MW, Kircher M, Hill AJ et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1–2), 57–66 (2016).
17. Lo YM, Zhang J, Leung TN et al. Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 64(1), 218–224 (1999).
18. Korabecna M, Opatrna S, Wirth J et al. Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease. *Ann. N. Y. Acad. Sci.* 1137(1), 296–301 (2008).

19. Tamkovich SN, Cherepanova AV, Kolesnikova EV et al. Circulating DNA and DNase activity in human blood. *Ann. N. Y. Acad. Sci.* 1075, 191–196.

20. Yao W, Mei C, Nan X, Hui L. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study. *Gene* 590(1), 142–148 (2016).

21. Pokrywka A, Zembron-Lacny A, Baldy-Chudzik K, Orysiak J, Sitkowski D, Banach M. The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation. *Arch. Med. Sci.* 11(6), 1156–1163 (2015).

22. Atamaniuk J, Vidotto C, Tschan H, Bachl N, Stuhlmeier KM, Muller MM. Increased concentrations of cell-free plasma DNA after exhaustive exercise. *Clin. Chem.* 50(9), 1664–1668 (2004).

23. Arvanitis A, Farioumis F, Rentzos A, Wolf M, et al. Cell-free DNA as a new marker of vascular inflammation. *Ann. N. Y. Acad. Sci.* 1137(1), 292–302 (2008).

24. Barlow J, Birdsall I, et al. Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. *J. Circ. Biomark.* 5, 1–6 (2016).

25. O’Connell GC, Petrone AB, Tennant CS et al. Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation. *Brain Inj.* 31(10), 1369–1375 (2017).

26. Chang CPY, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT. Elevated cell-free serum DNA detected in patients with myocardial infarction. *Clin. Chim. Acta* 327(1–2), 95–101 (2003).

27. Lo YMD, Rainer TH, Chan LYS, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. *Clin. Chem.* 46(3), 319–323 (2000).

28. Margraf S, Lüters T, Reijnen P, Altrichter J, Scholz M, Windolf J. Neutrophil-derived circulating free DNA (CF-DNA/NETs): a potential prognostic marker for posttraumatic development of inflammatory second hit and sepsis. *Shock* 30(4), 352–358 (2008).

29. Thierry AR, El Meshaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev.* 35(3), 347–376 (2016).

30. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. *Ann. N. Y. Acad. Sci.* 1313(1–2), 161–168 (2001).

31. Anker P, Stroun M, Maurice PA. Spontaneous extracellular synthesis of DNA released by human blood lymphocytes. *Cancer Res.* 36(8), 2832–2839.

32. Bronkhorst AJ, Wentzel JF, Aucamp J, van Dyk E, du Plessis L, Pretorius PJ. Characterization of the cell-free circulating tumor DNA. *Biochim. Biophys. Acta* 1863(1), 157–165 (2016).

33. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC – challenges to implementing cfDNA-based screening and MRD detection. *Nat. Rev. Clin. Oncol.* 15(9), 577–586 (2018).

34. Esposito A, Bardelli A, Criscitiello C et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. *Cancer Treat. Rev.* 40(5), 648–655 (2014).

35. Moulitre F, El Meshaoudi S, Gongora C et al. Circulating cell-free DNA from colorectal cancer patients may reveal high *KRAS* or *BRAF* mutation load. *Transl. Oncol.* 6(3), 319–328 (2013).

36. Forshew T, Murzaza M, Parkinson C et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Sci. Transl. Med.* 4(136), 136ra68 (2012).

37. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. *Proc. Natl Acad. Sci. USA* 108(23), 9530–9535 (2011).

38. Guo N, Lou F, Ma Y et al. Circulating tumor DNA detection in lung cancer patients before and after surgery. *Sci. Rep.* 6, 33519 (2016).

39. Newman AM, Lovejoy AF, Klass DM et al. Integrated digital error suppression for improved detection of circulating tumor DNA. *Nat. Biotechnol.* 34(5), 547–555 (2016).

40. Lanman RB, Mortimer SA, Zill OA et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. *PLoS ONE* 10(10), e0140712 (2015).

41. Odegaard JJ, Vincent JJ, Mortimer S et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. *Clin. Cancer Res.* 24(15), 3539–3549 (2018).

42. Quan P, Sauzade M, Brouzes E. dPCR: A Technology Review. *Sensors* 18(4), E1271 (2018).

43. Hu Y, Ulrich BC, Supplee J et al. False-positive plasma genotyping due to clonal hematopoiesis. *Clin. Cancer Res.* 24(18), 4437–4443 (2018).

44. Swanton C, Venn O, Aravanis A et al. Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. *J. Clin. Oncol.* 36(Suppl. 15), 12003 (2018).
45. Razavi P, Li BT, Brown DN et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. *Nat. Med.* 25(12), 1928–1937 (2019).

46. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. *Proc. Natl Acad. Sci. USA* 109(36), 14508–14513.